Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).

Inclusion criteria

• . Subjects voluntarily participate and sign the informed consent form;
• . Age≥ 50 years old, gender is not limited;
• . Confirmed presence of active CNV secondary to nAMD in the macula of study eye;
• . The total area of all types of lesions in the study eye \< 30 mm2;
• . The Best Corrected Visual Acuity (BCVA) detected by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart in the study eye is 63\~19 letters (including boundary values), which is equivalent to 20/63 to 20/400 of the Snellen Eye Chart;
• . The BCVA detected by the ETDRS eye chart in the non-study eye is not less than 19 letters, which is equivalent to 20/400 of the Snellen Eye Chart;
• . The study eye has received at least 2 episodes of intravitreal anti- VEGF therapy within 6 months prior to screening and has responded within two weeks of the lead-in period of anti-VEGF standard therapy (Aflibercept injection);
• . At screening, the blood pregnancy test result of females of childbearing potential (e.g., females who have not undergone surgical sterilization or less than 1 year after menopause) is negative. Male and female subjects of childbearing potential agree to use effective contraception throughout the study and for at least 12 months after dosing.

Exclusion criteria